B&B Tools AB

Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- * 82% of patients with pancreatic neuroendocrine tumors (NET) experienced clinical benefit when treated with daily RAD001 and monthly Sandostatin LAR

Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- * Novel vaccine produced protective immune response against broad range of representative meningococcal B strains in more than 95% of infants tested[1]

Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- * GALIANT[*] study in more than 2,400 patients shows Galvus as effective as commonly prescribed TZD drugs when added to metformin[1]

Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- * Regulatory applications to be submitted worldwide for RAD001, proposed brand name Afinitor®; first submissions filed in the US, EU and Switzerland * Data showing that RAD001 more than doubles time without tumor growth and reduced risk of disease progression by 70% now published in The Lancet

Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- * Data presented at European Society of Cardiology congress confirm Rasilez is effective in difficult-to-treat patients with obesity, heart failure and diabetes[1],[2],[3]

Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- * New 10mg strength offers increased treatment flexibility and more convenient dosage form

Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- * Aurograb(TM) decision reached after Phase II results show lack of efficacy as an add -on therapy for life-threatening bacterial infections

Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- * Clinical data showing unprecedented 89% reduction in risk of GIST relapse with use of Glivec after surgery are basis for FDA, EMEA, Swissmedic filings

Novartis International AG (SWF:NOVN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- * Lucentis is only approved therapy to demonstrate improvement in vision and vision-related function in vast majority of wet AMD patients * NICE decision secures access to innovative medication for eligible patients with wet AMD in England and Wales

Novartis International AG (NVS) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- * Delivery of Fluvirin supports planning and scheduling of public health influenza vaccination efforts * At least 20 million doses available by the end of September, when widespread vaccination campaigns usually begin * Additional manufacturing capacity recently approved by FDA for Fluvirin pre-filled syringes